Anebulo Pharmaceuticals Reports Q4 and FY25 Financial Results and Recent Updates

• Anebulo Pharmaceuticals reports FY25 financial results • Announces first subjects dosed in Phase 1 study of IV formulation of lead drug candidate selonabant • Selonabant in development for acute cannabis-induced toxicity treatment • Focuses on safety, tolerability, and pharmacokinetics in children • Recent updates and highlights on drug development

AUSTIN, Texas — Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) has reported its financial results for the fiscal year ended June 30, 2025, along with significant updates on its drug development pipeline. The company, which specializes in treating cannabis-induced toxicity, reported a net loss of $8.5 million for the year, compared to a net loss of $8.2 million in the previous fiscal year Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

The company's operating expenses for the year increased by approximately $1.0 million to $9.2 million, primarily driven by increased research and development (R&D) expenses. These expenses rose due to pre-clinical and clinical studies, as well as direct third-party costs related to the development of its lead drug candidate, selonabant Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

In a notable development, Anebulo announced that the first subjects have been dosed in a Phase 1 single ascending dose (SAD) study of an intravenous (IV) formulation of selonabant. The study aims to evaluate the safety, tolerability, and pharmacokinetics of the drug administered intravenously in healthy adult subjects aged 18 to 25 years Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

According to Richie Cunningham, Chief Executive Officer of Anebulo, the company has made significant progress towards its goal of providing the first emergency antidote for acute cannabis-induced toxicity in children. The IV formulation of selonabant is being developed as a potential treatment for pediatric patients with acute cannabis-induced toxicity, which is considered a more serious condition than in adults Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

The company has also been awarded the second-year tranche of a collaborative grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH), providing support for the ongoing SAD study. This grant, under award number U01DA059995, totals $994,300 Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

Anebulo's financial results also highlighted a net loss of $2.1 million in the fourth quarter of fiscal 2025, compared to a net loss of $1.3 million in the same period in fiscal 2024. The company reported operating expenses of $2.3 million in the fourth quarter, up from $1.3 million in the same period in fiscal 2024 Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

The company's cash and cash equivalents stood at $11.6 million as of June 30, 2025, with an additional $3 million available through a loan agreement Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

In addition to its financial updates, Anebulo announced that it has successfully scaled up the IV formulation of selonabant for initial clinical safety studies and initiated a Phase 1 SAD study in September 2025. The company believes that the IV formulation offers a faster timeline to approval relative to the adult oral product Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].